Co-Diagnostics (CODX) announced that it has signed a strategic Memorandum of Understanding with a regional manufacturing and distribution company located in the Kingdom of Saudi Arabia, to explore a joint venture that would be granted a license to develop, manufacture, and sell Co-Dx intellectual property throughout the Middle East and North Africa, including the company’s upcoming Co-Dx PCR point-of-care platform. According to the MOU, the KSA partner company in the JV would contribute local operational support, access to infrastructure, personnel, regulatory expertise, and other mission-critical resources in furtherance of the JV’s objectives across MENA countries, similar to the company’s operations in India through its Indian JV, CoSara Diagnostics Pvt Ltd.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CODX:
- Co-Diagnostics performs in silico analysis of primers sets for chikungunya virus
- Co-Diagnostics Earnings Call: Progress Amid Financial Struggles
- Co-Diagnostics Faces Financial Challenges and Regulatory Hurdles Amidst Hold Rating
- Co-Diagnostics Reports Q2 2025 Financial Results
- Is CODX a Buy, Before Earnings?